A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: careful (81), measured (540)

Cisplatin and Etoposide PO

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER CISPLATIN-ETOPOSIDE (oral) Regimen Cervix-Cisplatin-Etoposide PO Indication Treatment of partia
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Cervical-cancer/CisplatinandEtoposidePO.pdf

Irinotecan Ver 1.2

Description
Chemotherapy Protocol COLORECTAL CANCER Regimen IRINOTECAN Colorectal Cancer– Irinotecan Indication Second line treatment of advanced c
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/IrinotecanVer12.pdf

Capecitabine (14 day)

Description
Chemotherapy Protocol COLORECTAL CANCER CAPECITABINE (14 day) Regimen • Colorectal Cancer – Capecitabine (14 day) Indication • Metastatic
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/Capecitabine14day.pdf

Neuroendocrine-Cisplatin-Fluorouracil-Streptozocin

Description
Chemotherapy Protocol NEUROENDOCRINE CISPLATIN-FLUOROURACIL-FOLINIC ACID-STREPTOZOCIN (FCiSt) Regimen • Neuroendocrine – Cisplatin-Fluorou
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Endocrinecancer/Neuroendocrine-Cisplatin-Fluorouracil-Streptozocin.pdf

Erdafitinib

Description
Regimen • Urothelial - Erdafitinib Chemotherapy Protocol UROTHELIAL CANCER ERDAFITINIB Indication • Monotherapy treatment of unresectable or m
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Erdafitinib.pdf

Audit and Risk Committee ToR March 2026

Description
Audit and Risk Committee Terms of Reference Version: 8 Date Issued: Review Date: Document Type: 10 March 2026 January 2027 Committee T
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2026-Trust-documents/Audit-and-Risk-Committee-ToR-March-2026.pdf

Audit and Risk Committee ToR March 2025

Description
Audit and Risk Committee Terms of Reference Version: 7 Date Issued: Review Date: Document Type: 11 March 2025 January 2026 Committee T
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2025-Trust-documents/Audit-and-Risk-Committee-ToR-March-2025.pdf

Audit and Risk Committee ToR Jan 2023

Description
Audit and Risk Committee Terms of Reference Version: 5 Date Issued: Review Date: Document Type: 31 January 2023 January 2024 Committee
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2023-Trust-documents/Audit-and-Risk-Committee-ToR-Jan-2023.pdf

Papers Trust Board - 30 January 2020

Description
Date Time Location Chair Apologies Agenda Trust Board – Open Session 30/01/2020 9:00 - 11:45 Conference Room, Heartbeat Education Centre,
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2020/Papers-Trust-Board-30-January-2020.pdf

RGDP-Cisplatin-Dexamethasone-Gemcitabine-Rituximab

Description
Chemotherapy Protocol LYMPHOMA CISPLATIN-DEXAMETHASONE-GEMCITABINE-RITUXIMAB (RGDP) Regimen • Lymphoma – RGDP-Cisplatin-Dexamethasone-G
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RGDP-Cisplatin-Dexamethasone-Gemcitabine-Rituximab.pdf
271 to 280 of 1000
Previous … 26 27 28 29 30 … Next